Vascular Biogenics stock up 34% in pre-market trade after positive cancer drug trial results
Phase III Study Shows Genentech’s Actemra® (tocilizumab) Maintained Steroid-Free Remission in People With Giant Cell Arteritis (GCA)
Genentech’s Cancer Immunotherapy TECENTRIQ™ (Atezolizumab) Shrank Tumors in People with Previously Untreated Advanced Bladder Cancer
Chugai Announces License Agreement for Recycling Antibody SA237
Genentech’s Gazyva® Showed Superior Progression-Free Survival Compared to Rituxan® in People with Previously Untreated Follicular Lymphoma
First movers, including Bristol-Myers, and firms that can aggregate a portfolio of immuno-oncology therapies will be positioned well.
These quality funds with smaller asset bases have portfolios built around solid companies.
Large drugmakers are out of favor, but some good funds are banking on a rebound.